T
he Food and Drug Administration (FDA) rule for limiting aluminum content in total parenteral nutrition (TPN) preparations continues to cause concerns among health care professionals, especially pharmacists. 1 The federal regulation applies to drug manufacturers and not pharmacy practitioners and has three main objectives: (1) that the labels of all large-and smallvolume parenterals used to prepare TPN formulations state the maximum aluminum concentration (in micrograms per liter) at expiration, (2) that the data submitted to FDA supporting the label claim must include information that describes a validated assay method for aluminum determination, and (3) that objectives 1 and 2 allow, but not mandate, health care professionals to calculate a patient's exposure to aluminum when receiving TPN and take actions that limit intake in patients susceptible to aluminum toxicity. The statement on clinical limits for aluminum levels required by FDA for inclusion in the package insert contains this warning: "Levels of aluminum at greater than 4 to 5 µg/kg/ day accumulate aluminum at levels associated with central nervous system and bone toxicity."
2 Although the FDA rule does not require pharmacists to intervene whenever a TPN formulation contains more aluminum than a daily dosage of 5 µg/kg, we believe that practicing pharma-cists have a professional responsibility to calculate the daily aluminum load of compounded TPN preparations and that this information should be reported on the label of each admixture dispensed. Such calculations can be performed manually, but ideally the total aluminum content in a TPN preparation should be included in the software programs used for automated compounding devices.
Since Abbott Laboratories is already in compliance with FDA's mandate, 1 we calculated the theoretical aluminum exposure associated with its products (except for multivitamin injections) in clinically relevant nutrition support scenarios for infants and adults. 3, 4 The calculations were based on the maximum aluminum concentration at expiration reported on the label of each product. The desired outcome for patients receiving TPN would be limiting cumulative aluminum exposure to no more than 5 µg/kg/day. Tables 2 and 3 list the calculated aluminum loads in TPN admixtures prepared from small-and largevolume parenteral nutrient additives prescribed for a given clinical situation. To provide adequate amounts of macro-and micronutrients for both adults and infants, the total aluminum exposure far exceeds the clinical limits set forth in the warning statement required in the package inserts for these commercial products. In admixtures for adults, most of the aluminum content is attributable to the concentration of aluminum in calcium gluconate injection and inorganic phosphates injection. In TPN admixtures for infants, another major source of aluminum is the age-essential amino acid cysteine hydrochloride.
The pharmacist has few options for reducing the aluminum load in TPN formulations. For example, switching to products packaged in plastic vials may result in lower concentrations of aluminum. An example is Sodium Phosphates Injection, USP (Abbott list no. 7391-72), a 10-mL plastic vial, which contains only 180 µg of aluminum per liter, compared with the example listed in Table 1 (Abbott list no. 3295-51), a 50-mL glass vial, which contains 28,000 µg/L. Although the package size makes it inconvenient to prepare TPN admixtures with automated compounding devices, one could meet FDA's clinical limits for aluminum in adults weighing 70-80 kg by switching to the product in the plastic container. However, the other TPN formulations presented in Tables 2 and 3 still do not have a reasonable solution. Therefore, in most clinical cases, there are no "appropriate substitutions if the patient is in the high risk group," as suggested by FDA. 1 Providing mineral supplementation in TPN formulations on alternate days or reductions in certain nutrient intakes may be considered but would result in some compromise in the effectiveness of TPN therapy. We do not recommend that pharmacists choose alternative electrolyte salts solely to reduce aluminum exposure, especially when this involves calcium and phosphate in TPN admixtures. 5 For example, a change in calcium salts to either acetate or chloride could introduce disastrous consequences if the phosphate content in the same TPN formulation is not reduced accordingly. Parenteral organic phosphate salts may be an alternative, since they, like the organic calcium gluconate salt, have limited dissociation of free interacting ions to form calcium phosphate precipitate in TPN admixtures. This is not possible at present, since parenteral organic phosphate salts are not approved for use in the United States. Hence, efforts to reduce aluminum concentrations in these products should come from improved manufacturing techniques that have existing FDA approval or developing new formulations with low aluminum content.
Finally, certain drug additives can also contribute aluminum, but they do not fall under the proposed agency mandate. In most cases, however, the amounts of aluminum contributed from non-TPN drug products, with the exception of albumin, are very small. Fortunately, the routine use of albumin via TPN admixtures is of questionable clinical value and has been largely abandoned by most clinicians. 6 A high aluminum content in TPN admixtures is largely the result of three parenteral nutrient additives: calcium gluconate, inorganic phosphates injection (sodium or potassi-um), and cysteine hydrochloride. Although available products may meet the validation and labeling requirements of the FDA mandate, limiting aluminum exposure from TPN therapy to less than 5 µg/kg/day will not be possible for most patients. 
